BOCA RATON, Fla. (HedgeWorld.com) - Thomas H. McLain, chairman and chief executive of Nabi Biopharmaceuticals, has sent its blue cards, for consent revocation, out to stockholders in the hopes of containing a challenge from hedge fund Third Point LLC, New York.

Late last month, Third Point and its principal, Daniel S. Loeb, initiated a consent solicitation in an effort to put five nominees of its own on Nabi's board.